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Abstract
Background: Alveolar soft-part sarcoma (ASPS) is an extremely rare, highly vascular soft tissue
sarcoma affecting predominantly adolescents and young adults. In an attempt to gain insight into
the pathobiology of this enigmatic tumor, we performed the first genome-wide gene expression
profiling study.
Methods: For seven patients with confirmed primary or metastatic ASPS, RNA samples were
isolated immediately following surgery, reverse transcribed to cDNA and each sample hybridized
to duplicate high-density human U133 plus 2.0 microarrays. Array data was then analyzed relative
to arrays hybridized to universal RNA to generate an unbiased transcriptome. Subsequent gene
ontology analysis was used to identify transcripts with therapeutic or diagnostic potential. A subset
of the most interesting genes was then validated using quantitative RT-PCR and
immunohistochemistry.
Results: Analysis of patient array data versus universal RNA identified elevated expression of
transcripts related to angiogenesis (ANGPTL2, HIF-1 alpha, MDK, c-MET, VEGF, TIMP-2), cell
proliferation (PRL, IGFBP1, NTSR2, PCSK1), metastasis (ADAM9, ECM1, POSTN) and steroid
biosynthesis (CYP17A1 and STS). A number of muscle-restricted transcripts (ITGB1BP3/MIBP,
MYF5, MYF6 and TRIM63) were also identified, strengthening the case for a muscle cell progenitor
as the origin of disease. Transcript differentials were validated using real-time PCR and subsequent
immunohistochemical analysis confirmed protein expression for several of the most interesting
changes (MDK, c-MET, VEGF, POSTN, CYP17A1, ITGB1BP3/MIBP and TRIM63).
Conclusion: Results from this first comprehensive study of ASPS gene expression identifies
several targets involved in angiogenesis, metastasis and myogenic differentiation. These efforts
represent the first step towards defining the cellular origin, pathogenesis and effective treatment
strategies for this atypical malignancy.
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Background
Alveolar soft-part sarcoma (ASPS) is an extremely rare (1
diagnosis per 10 million population per year) soft tissue
sarcoma with an indolent course and generally poor prog-
nosis [1-3]. The disease manifests in young adults (15–35
years), where it is usually diagnosed from a painless mass
in the lower limbs, head or neck [1,4]. ASPS is surprisingly
slow growing with a clinical course averaging 15 years,
where late stage disease is associated with metastasis to
multiple sites including the lungs, bone, lymph nodes and
brain [4]. The protracted ontogeny of ASPS makes it rela-
tively resistant to classical chemotherapy and current
treatment options are limited to surgical resection and
localized radiotherapy.
Histologically, ASPS is composed of organoid nests of
polygonal tumor cells encompassed by a dense capillary
vasculature, giving rise to the 'alveolar' appearance [1,2].
In spite of several reports suggesting ASPS arises from a
myogenic progenitor, the tissue ontogeny of ASPS is still
contested, primarily because consistent detection of mus-
cle markers (e.g. MYOD1 or MYOG) has not been demon-
strated [5,6]. ASPS cells also contain numerous periodic
acid Schiff-positive, diastase-resistant crystalline struc-
tures, recently identified as containing monocarboxylate
transporter 1 (MCT1) and the cellular chaperone CD147
[7].
At the cytogenetic level, ASPS exhibits a conserved abnor-
mality in the form of an unbalanced translocation
der(17)t(X;17)(p11;q25) which fuses the N-terminal
region of the alveolar soft part locus gene (ASPL), located
at 17q25, to the C-terminal region of the transcription fac-
tor E3 (TFE3), located at Xp11. Two alternative fusion
junctions have been observed resulting in the expression
of two distinct fusion transcripts, ASPL-TFE3 type 1 and
type 2 [8]. TFE3 is a ubiquitous basic helix-loop-helix
(bHLH) leucine zipper transcription factor, which binds
positive strand e-box motifs [CANNTG] [9]. High-affinity
interactions with DNA occur when TFE3 is present as a
homodimer or when combined with other bHLH factors
including MITF, TFEB and TFEC [10]. Conversely, ASPL
has only been partially characterized as a tethering protein
that forces retention of GLUT4-containing vesicles in the
cytoplasm in the absence of insulin [10,11].
The current consensus is that aberrant TFE3 transcrip-
tional activity modulated by the ASPL fusion partner is
likely responsible for elements of ASPS pathogenesis. Fur-
ther support for the primacy of TFE3 comes from the
detection of alternate TFE3 fusion proteins (PRCC-TFE3,
PSF-TFE3, NONO-TFE3) in a subset of renal carcinomas
[12-15]. As regards novel properties of ASPL-TFE3, one
study using an anti-TFE3 antibody demonstrated 'aber-
rantly strong' nuclear staining in ASPS patients suggesting
either enhanced nuclear trafficking, protein stability or
expression levels [16]. More recently, fusion proteins con-
taining TFE3 have been shown to directly activate tran-
scription of c-MET (Hepatocyte growth factor receptor)
through a consensus e-box [17]. Given that c-MET plays
an important role in cell survival and angiogenesis, this
important observation forges a link between ASPL-TFE3
and disease pathogenesis, intimating that genes with sim-
ilar promoter elements may also be activated [18].
Therefore, as a slow growing yet highly vascular sarcoma,
ASPS is an intriguing candidate for gene expression analy-
sis. In this study, freshly isolated patient RNA was used to
generate a transcriptomic profile for ASPS. Results demon-
strated elevated expression for factors involved in angio-
genesis including: angiopoietin-like 2 (ANGPTL2), the
HGF receptor (c-MET), Hypoxia-Inducible factor 1α
(HIF1A), midkine (MDK) and vascular endothelial
growth factors A/B (VEGF/VEGFB). Further exploration
identified muscle-specific beta 1 integrin binding protein
(ITGB1BP3/MIBP), muscle-specific RING finger protein 1
(TRIM63) and Myogenic factors 5 and 6 (MYF5/6) as
potential ASPS markers. Overall, these data identify
molecular targets with the potential to aid the diagnosis
and treatment of ASPS.
Methods
A list of antibody sources, dilutions, retrieval conditions
and positive control tissues used in immunohistochemi-
cal analysis is provided [see Additional file 1]. Unless oth-
erwise indicated in the following methods, all other
chemicals and inhibitors were from Sigma (St. Louis,
MO).
ASPS diagnosis and RNA isolation
Tumors were obtained from surgery following informed
consent under NCI clinical research protocol 05-C-N138,
approved by the U.S. National Cancer Institute (NCI)
Institutional Review Board (IRB), and with the assistance
of the Alliance Against Alveolar Soft-Part Sarcoma
(TAAASPS). This research is in compliance with the Hel-
sinki Declaration for conduct of research utilizing human
subjects. A representative tumor sample (0.5–1.0 cm) was
fixed in buffered 10% formalin for histopathology. The
following criteria were employed for the diagnosis of
ASPS: the presence of organoid nests of cells surrounded
by endothelial-lined vascular channels in H&E stained
material [1]; cytoplasmic PAS positive crystals following
digestion with diastase [7]; the presence of the ASPL-TFE3
type 1 or type 2 fusion transcript [8], nuclear staining with
antibodies to the transcription factor TFE3 [16] and to
either the ASPL-TFE3 type 1 or type 2 fusion protein [19].
For isolation of RNA, a portion of tumor tissue was imme-
diately placed in RNA later solution (Ambion, Austin, TX)
and stored at 4°C. Total RNA was prepared using the RNe-BMC Cancer 2009, 9:22 http://www.biomedcentral.com/1471-2407/9/22
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asy Fibrous Midi Kit (Qiagen, Valencia, CA) according to
the manufacturer's instructions. The concentration of
RNA was determined on a Nanodrop spectrophotometer,
and the A260/A280 values were greater than 1.9. The
integrity and size distribution of RNA were evaluated on
1% denaturing NuSieve agarose gels (FMC, Rockland,
ME) followed by ethidium bromide staining.
Reverse transcription
Total RNA was isolated from cells using the RNeasy mini
kit (Qiagen, Valencia, CA) and reverse transcribed using
Omniscript RT according to the manufacturers' instruc-
tions. A standard reaction comprised 2 μg total RNA, 0.5
mM each dNTP, 2 μM random decamers (Ambion, Aus-
tin, TX) and 4 units of reverse transcriptase in 20 μl total
volume of 1× RT buffer. The reaction was allowed to pro-
ceed for 90 min at 37°C and the cDNA product diluted to
1 μg/ml and stored at -80°C.
Microarray data acquisition
Microarray data was collected at Expression Analysis, Inc.
(Durham, NC) using the GeneChip® Human U133 plus
2.0 Array (Affymetrix), according to standardized operat-
ing procedures. Overall, analysis was performed on RNA
from seven ASPS patients and universal RNA, where all
samples were analyzed in duplicate. The universal refer-
ence RNA (Clontech) is a mixture of RNAs from a collec-
tion of adult human tissues (male and female)
representing a broad range of expressed genes. Affymetrix
array data files (.CEL) have been deposited with the Gene
Expression omnibus http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE13433.
Microarray data analysis
The Genesifter suite (VizX labs, Seattle, WA) was used for
analysis of microarray data. In brief, compressed .CEL files
containing array data were loaded into the Genesifter web
portal http://www.genesifter.net. Using the advanced
upload function, probe-level data was then compiled,
normalized and transformed using GC-RMA [20]. Pair-
wise analysis was then performed comparing universal
RNA arrays with ASPS patient arrays. The following crite-
ria were applied to filter the differentially expressed tran-
script list, a fold change of >3 and a Wilcoxon rank sum
test where p < 0.05 with Benjamini-Hochberg estimation
of false discovery rate (FDR). The list of differentially reg-
ulated transcripts was then exported into excel for gene
ontogeny analysis.
Quantitative RT-PCR
SYBR Green chemistry was used to detect primer specific
amplicons. For each reaction, 12.5 μl Quantitect SYBR
Green PCR mastermix (Qiagen, Valencia, CA) was diluted
1:2 in DNase free water containing 5 ng cDNA and 1 μM
of specific primer pair. Reactions were performed in trip-
licate and universal 18S RNA primers (Ambion, Austin,
TX) were used to normalize cDNA amplification. The
fluorochrome ROX, included in the PCR mastermix, was
used as a passive reference. Reactions were performed
using an ABI7500 thermocycler (Applied Biosystems, Fos-
ter City, CA). Cycling conditions consisted of a single 10
min/95°C activation step followed by 50 cycles of 95°C/
15 s, 60°C/60 s and 72°C/60 s with fluorescence meas-
urements taken in the elongation step of each cycle. Fold
changes and p values were then calculated by copying CT
data into a Superarray analysis template (Superarray Inc.
Frederick, MD). For each primer pair melting curve analy-
sis was used to confirm the presence of a single amplicon.
Sequences of primers used in quantitative RT-PCR are pro-
vided [see Additional file 2].
Immunohistochemistry
In brief, tissue sections (5 μm) affixed to glass slides, were
deparaffinized and treated for 15 minutes in methanol
containing 0.6% H2O2 followed by either 1 mM EDTA
(pH 8.0) or 10 mM citrate buffer (pH 6.0) in a microwave
vacuum histoprocessor (RHS-1; Milestone, Italy). The
temperature was gradually increased to 100°C over 10
minutes and maintained at 100°C for an additional 10
minutes. Sections were cooled, rinsed sequentially in H2O
and PBS for 10 minutes each. Primary antibodies, used at
dilutions indicated [see Additional file 1] were overlayed
onto the tissue sections and incubated either overnight or
for 30 min at room temperature. Sections were rinsed in
PBS for 10 minutes and incubated with the appropriate
secondary antibody for 30 minutes. Sections were rinsed
in PBS for 10 minutes and processed according to instruc-
tions detailed in the detection kits.
Results
Microarray analysis
For seven patients with confirmed ASPS, fresh tumor spec-
imens were obtained directly after surgery, total RNA was
extracted, quality assured and then reverse transcribed to
cDNA. Variables for these tumors in terms of sex, age, pri-
mary/metastatic disease and ASPL-TFE3 fusion type (1/2)
are shown in Table 1. After reverse transcription, the seven
Table 1: ASPS Patient Demographics
Patient Age Sex ASPL-TFE3 Fusion Type Primary or Metastasis
1 26 M 2 P (Thigh)
2 39 F 1 M (Mandible)
3 25 M 2 P (Hip)
41 5 F 2 M  ( L u n g )
51 4 M 2 P  ( C a l f )
6 27 F 1 P (Thigh)
72 2 M 2 M  ( L u n g )
ASPL-TFE3 fusion type determined using RT-PCR according to 
Ladanyi et al. 2001 [8]BMC Cancer 2009, 9:22 http://www.biomedcentral.com/1471-2407/9/22
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cDNAs were each hybridized to duplicate high-density
U133 plus 2 microarrays (~47,400 transcript). Two addi-
tional arrays, hybridized to universal cDNA (Promega)
were included as standards. The choice of universal RNA
normalization, as opposed to normalizing against a single
normal tissue or alternate pooled sarcoma ensured that an
relatively unbiased (basal) gene expression profile was
generated. Analysis of combined ASPS patient arrays ver-
sus universal RNA was performed using the pairwise anal-
ysis function within GeneSifter (VizX labs), where the
duplicate universal RNA arrays (control group) were ana-
lyzed against duplicate arrays for all seven ASPS patients
(test group). A list of differentially expressed transcripts
was then generated according to the following criteria;
GC-RMA normalization, <0.05 adjusted p-value, Ben-
jamini and Hochberg false discovery estimates with > +/-
3 fold changes in expression. The generated output con-
sisted of 7367 differentially regulated transcripts, where
4731 (64.2%) were downregulated and 2636 (35.7%)
showed upregulated expression [see Additional file 3].
Validation and gene ontology analysis
Microarrary data was then interrogated with reference to
gene ontology (GO) databases with the overall aim of
identifying a subset of genes for validation with quantita-
tive RT-PCR. Transcripts with potential disease relevance
or drugability, such as those implicated in angiogenesis,
metastasis, proliferation and drug resistance were of par-
ticular interest. Reference databases used to mine gene
ontology information included Ingenuity Pathways Anal-
ysis http://www.Ingenuity.com, Entrez Gene http://
www.ncbi.nlm.nih.gov, Genecards http://www.gene
cards.org/index.shtml and Symatlas http://symat
las.gnf.org/SymAtlas/. A subset of relevant genes was then
validated using SYBR-green based quantitative RT-PCR. In
total, primers were designed for 61 genes and expression
relative to universal RNA determined for all seven ASPS
patient samples. A summary of results from both microar-
ray analysis and quantitative RT-PCR, subdivided into
molecular function is shown in Figure 1. Results demon-
strated concordance in direction of change between tech-
niques with acceptable p-values, supporting differential
regulation of the gene subset. However, for several tran-
scripts a significant discrepancy was evident in the extent
of change between the different techniques. Although
some differences can be anticipated based on primer/
probe specificity, methods for calculating fold change and
dynamic range of detection, results for several transcripts
were considerable (PRM1/2 and UMOD). For example,
protamine 1 was downregulated 1160.1 fold by microar-
ray versus 75.4 fold for RT-PCR. This result should be
regarded as a 'zero' result for the microarray rather than a
true representation of fold change and highlights a poten-
tial drawback in the use of universal RNA as a standard
given that it favors extreme differentials that may reside
outside of the quantitation range of a technique.
Immunohistochemistry
A tissue array of paraffin-embedded ASPS tumors was
then constructed for immunohistochemical (IHC) analy-
sis. Each array contained multiple sections from each of
the seven patients, where ASPS origin was confirmed by
staining with H&E, PAS/diastase and α-TFE3 antibody.
Staining protocols were then established using several
commercially available antibodies against targets identi-
fied during gene expression analysis. Representative
examples of IHC staining patterns for each experimental
antibody are shown in Figure 2. Results demonstrated that
an antibody against HIF-1α showed nuclear localized
staining consistent with the regulation of HIF-1α expres-
sion by hypoxia gradients. An Anti-VEGF antibody pro-
duced intense and consistent staining of endothelial cells,
highlighting the potential importance of this mediator in
establishing ASPS morphology and potentially also in dis-
ease progression. A similar staining pattern was evident
using antibodies against the secreted protein Periostin
(POSTN), suggesting that endothelial cells are either the
source of or ultimate target of this molecule. Conversely,
midkine (MDK) staining was found across all patients and
localized to the cytoplasm of the ASPS tumor cells them-
selves. Interestingly, for c-MET, all ASPS tumors were pos-
itive with expression localized to both cytoplasm and
nucleus, which is consistent with it's recognized cycling
between these two cellular compartments. Some of the
most intense staining was observed for an antibody
against CYP17A1, which localized to tumor cell cyto-
plasm. Lastly, antibodies against the muscle-specific pro-
teins ITGB1BP3/MIBP and TRIM63 reacted consistently
with ASPS tumor sections with cytosolic localization.
These experiments suggest that detection of mRNA
reflects, at least qualitatively, expression of protein. More
importantly, immunohistochemistry data provides confi-
dence that biological inferences can be drawn from the
broader transcriptomic analysis.
Discussion
Our current understanding of ASPS disease origin, patho-
genesis and effective treatment strategies is rudimentary.
In this study, we began to address these issues by generat-
ing a genome-wide ASPS transcriptome using freshly iso-
lated patient RNA. The quality of target RNA is a central
issue in successful gene expression analysis, especially
when using high-feature microarrays. Therefore, the deci-
sion was taken to focus efforts on RNA freshly isolated
from a small number of ASPS patients rather than utiliz-
ing degraded RNA from archived paraffin-embedded
specimens. Results demonstrated that ASPS has a molecu-
lar signature encompassing genes with therapeutic and
diagnostic potential (Figure 3). Similarly, identification ofBMC Cancer 2009, 9:22 http://www.biomedcentral.com/1471-2407/9/22
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elevated expression for several transcripts provided clues
towards the cellular origin of disease.
Altered expression of transcripts involved in the response
to hypoxia and angiogenesis suggests that these pathways
are active in ASPS and provides some of the most interest-
ing candidates for therapeutic intervention. The greatest
increase in angiogenesis-related genes was seen for angi-
opoietin-like 2 (ANGPTL2). Angiopoietins are hypoxia-
regulated members of the vascular endothelial growth fac-
tor (VEGF) family, where ANGPTL2 acts as an endothelial
survival factor that does not bind TIE1 or TIE2 [21].
Validation of Microarray Data for selected transcripts by Quantitative RT-PCR Figure 1
Validation of Microarray Data for selected transcripts by Quantitative RT-PCR. For a subset of genes identified as 
potentially interesting from GO analysis, quantitative RT-PCR analysis was performed to validate the extent and direction of 
change. Results are shown subdivided into molecular function, with fold change values for both microarray and quantitative RT-
PCR shown along with heat map representation of individual patient values with +/- 20 fold limits.BMC Cancer 2009, 9:22 http://www.biomedcentral.com/1471-2407/9/22
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Increased expression was also observed for the master
transcriptional regulator of the response to hypoxia, HIF-
1α (HIF1A), which is interesting given that regulation of
HIF-1α occurs predominantly through a post-transla-
tional mechanism [22]. Similarly, enhanced expression of
Midkine (MDK), a hypoxia-induced growth factor
involved in cell survival and migration, provides a poten-
tial target for inhibition [23]. Here, we also confirm con-
sistent increases in expression of the hepatocyte growth
factor receptor (MET). In a recent study, ASPL-TFE3 and
other TFE3 fusion proteins were shown to bind and
strongly activate the MET promoter [17]. Furthermore, in
cells expressing TFE3, inhibition of MET using siRNA or a
small molecule MET inhibitor impaired tumor growth. A
similarly important observation concerned elevated
expression of two members of the VEGF family, VEGF-A
and VEGF-B, supporting the utility of inhibitors such as
Bevacizumab in the treatment of ASPS [24]. Increased
expression of Stabilin (STAB1) may also contribute
towards an angiogenic phenotype, given that this scaven-
ger receptor is expressed on endothelial cells and inhibi-
tion with monoclonal antibodies has been shown to
prevent cord formation in vitro [25]. In a recent study,
RNA isolated from formalin-fixed paraffin-embedded
ASPS tumor material was subjected to focused microarray
analysis with emphasis on genes involved in angiogenesis
[26]. Overall, 18 genes were found to be upregulated >1.5
fold with 8 regulated >3 fold. Cross-comparison showed
that 7/18 of these genes (MDK, PTN, JAG1, TGFB1, NRP1,
HIF1A and TIMP2) were represented in our transcriptome
Analysis of marker protein expression using an ASPS tissue array Figure 2
Analysis of marker protein expression using an ASPS tissue array. Paraffin-embedded sections from seven 
ASPS tumors were arrayed on glass slides and analyzed by immunohistochemistry. For all sections, ASPS origin 
was confirmed by detection of intracellular granules using periodic-acid Schiff diastase (PAS/D) staining and nuclear reactivity 
when stained with an anti-TFE3 antibody. Images shown are representative of staining patterns for the majority tumors. All 
Images were captured at 350 × magnification.BMC Cancer 2009, 9:22 http://www.biomedcentral.com/1471-2407/9/22
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(which utilizes a 3-fold cut-off). These results are note-
worthy as they confirm several of our own observations
and highlight a possible role for JAG1. Overall, identifica-
tion of several angiogenic mediators (Angiopoietin-like 2,
c-MET, HIF-1α and VEGF) provides a molecular frame-
work for ASPS vascular histology and supports the use of
anti-angiogenic agents in treatment [24].
Increased expression of several mitogenic factors was also
noted. One example was Prolactin (PRL), a 23 kDa pep-
tide hormone implicated in a diverse range of processes
including lactation and cell proliferation [27]. Prolactin is
recognized as a breast cancer cell survival factor and prol-
actin inhibitors demonstrate the ability to inhibit cell pro-
liferation  in vitro and to slow tumor growth in mice
[28,29]. Further transcripts involved in growth regulation
showing upregulation included; insulin like growth factor
binding protein 1 (IGFBP1), Neurotensin receptor 2
(NTSR2) and proprotein convertase subtilisin/kexin type
1 (PCSK1).
Several genes broadly implicated in metastasis showed
elevated expression. Periostin (POSTN) is a 90 kDa disul-
phide-linked secreted protein which has homology to the
axon guidance protein fasciclin I [30]. Periostin is
expressed predominantly in fetal tissues and also in ovar-
ian cancer, where it binds αVβ3/αVβ5 integrins and pro-
motes cellular motility [31]. Neutralizing therapeutic
antibodies directed against Periostin have already under-
gone pre-clinical evaluation, with promising results [32].
Extracellular matrix protein 1 (ECM1) meanwhile is a
recently identified secreted glycoprotein, over-expressed
in several epithelial malignancies, recognized as capable
of promoting metastasis and angiogenesis [33]. A disin-
Potential ASPS diagnostic and therapeutic targets identified during the study Figure 3
Potential ASPS diagnostic and therapeutic targets identified during the study. Established therapeutic targets or 
those currently undergoing development are marked with a star.BMC Cancer 2009, 9:22 http://www.biomedcentral.com/1471-2407/9/22
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tegrin and metalloproteinase domain 9 (ADAM9) is a
membrane bound metalloprotease, which like the other
ADAM family members plays a role in cellular invasion,
metastasis and angiogenesis [34]. Along with proteolytic
activity, ADAM9 appears to function as an adhesion mol-
ecule mediating interactions with αvβ5 integrin [35]. This
protein is expressed in a variety of normal tissues and
shows elevated expression in certain cancers and under
conditions of cellular stress [36].
Aberrant expression was also noted for transcripts impli-
cated in embryonic development. Pregnancy-specific glyc-
oprotein 9 (PSG9) is a secreted glycoprotein belonging to
the CEA family. In colorectal cancer, PSG9 also shows ele-
vated expression [37]. However, the function of the anti-
gen is largely unknown, although an immunological role
has been suggested [38]. Equally, glycoprotein NMB
(GPNMB) is a type I membrane protein with homology to
the melanoma antigen pMEL17 [39]. This antigen has
been identified at the plasma membrane of several malig-
nancies including melanoma and glioma [39,40]. A
humanized toxin-conjugated NMB antibody was shown
to be effective in killing antigen-positive melanoma, sug-
gesting that this therapeutic may have potential in the
treatment of other NMB positive malignancies [41].
Enhanced expression was observed for Inhibin beta E
chain (INHBE), a subunit which contributes towards the
activin/inhibin pleotropic hormone axis. Inhibins are het-
erodimers of one α and one β subunit, whereas activins
are homo- or heterodimers of β subunits only. As mem-
bers of the extended TGF-β super family, these activins
play a number of roles including cell proliferation, differ-
entiation and apoptosis [42]. Two genes involved in ster-
oid biosynthesis, cytochrome P450-17A1 (CYP17A1) and
Steroid sulfatase (STS), also show increased expression.
CYP17A1 is an enzyme that converts pregnenolone and
progesterone to their 17- alpha-hydroxylated products
whereas STS catalyzes the conversion of sulfated steroid
precursors to estrogens.
With respect to defining ASPS cellular ontogeny, Symatlas
identified a preponderance of muscle-restricted genes in
the ASPS transcriptome (results not shown). Classical
markers of skeletal muscle development (myogenin,
myoblast determination protein 1, desmin and
myoglobin) were not detected at the mRNA level, mirror-
ing reports obtained elsewhere [6]. However, myogenic
factors 5 and 6 (MYF5/6), important members of the
myogenic basic helix-loop-helix (bHLH) family of tran-
scription factors, were upregulated. Interestingly, myo-
genic factors such as these bind to the same E-box
consensus motif [CANNTG] as TFE3 [43]. In terms of
myogenic differentiation, evidence suggests that MYF5 is
involved in progenitor cell proliferation whereas myob-
last determination protein 1 and myogenin are concerned
more with cell specialization and terminal differentiation
[44]. A further compelling candidate for an ASPS marker
was Muscle-Specific B1 Integrin Binding Protein
(ITGB1BP3/MIBP). Expression of this transcript was sig-
nificantly increased in ASPS relative to universal RNA
(1238 up microarray; 482 up QPCR) and according to
Symatlas is expressed primarily in skeletal muscle and
heart. A possible link to ASPS pathogenesis may be
inferred from one recent study showing that in myoblasts,
ITGB1BP3 suppresses fusion and terminal differentiation
[45]. This protein appears to function by selectively bind-
ing the α7β1 v laminin receptor and mediating reduced
laminin cell adhesion and matrix deposition [46]. Simi-
larly, muscle specific enolase 3 (ENO3) was upregulated
in all patients. This enzyme is a HIF-1α inducible gene
thought to be involved in striated muscle development
and regeneration [47,48]. Increased expression was simi-
larly observed for Muscle-specific RING finger protein 1
(TRIM63), an E3 ubiquitin ligase involved in the degrada-
tion of sarcomere-associated proteins such as troponin
[49]. In combination with atrogin-1, this protein is
thought to be involved in skeletal muscle atrophy [50]. A
further upregulated skeletal muscle restricted transcript
was Nebulin (NEB), a giant (800 kDa) protein that main-
tains the structural integrity of sarcomeres in skeletal mus-
cle [51]. ASPS cells are reported to contain cytoplasmic
granules containing monocarboxylate transporter 1
(MCT1) and the accessory protein Basigin (BSG/CD147)
[7]. A search of our array data identified increased expres-
sion of MCT1 but not CD147.
A group of smooth muscle restricted transcripts were sim-
ilarly upregulated. Fibroblast activation protein α (FAP) is
a gelatinase implicated in tissue remodeling and tumor
invasion expressed primarily in smooth muscle and also
found in some melanoma cell lines [52]. Sushi-repeat-
containing protein, X-linked 2 (SRPX2) is a poorly charac-
terized protein expressed primarily in smooth muscle and
neuronal tissue [53]. Finally, lysyl hydroxylase 2 (PLOD2)
is responsible for the production of stabilizing hydroxyly-
sine residues in collagens and shows highest expression in
smooth muscle [54].
Therefore, detection of two myogenic regulatory factors
MYF5/MYF6 along with several other muscle-specific
transcripts including ITGB1BP3/MIBP and TRIM63 seems
to favor a myogenic progenitor [44]. Several reports have
explored the possible myogenic origin of ASPS [55-61].
Within these, there are conflicting reports of expression of
the muscle-specific factor MyoD1 [58-60]. Our data sug-
gest that MyoD1 is absent whereas family members MYF5
and MYF6 are expressed. We also concur with results
showing that ASPS is myogenin negative [61]. Therapeutic
targeting of muscle-specific protein may also have poten-
tial. For example, experiments using siRNAs are currentlyBMC Cancer 2009, 9:22 http://www.biomedcentral.com/1471-2407/9/22
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underway to determine whether the reported ability of
ITGB1BP3/MIBP to inhibit myoblasts terminal differenti-
ation also extends to ASPS cells [45].
Conclusion
In conclusion, the work presented here comprises the first
genome-wide microarray analysis of ASPS; generated
using RNA isolated from tumors at the time of surgery.
The approach used strongly suggests that for rare tumors
such as ASPS, microarray analysis of small number of
fresh tumor RNA samples is preferable to analysis of RNA
from large numbers of archival specimens. Results iden-
tify targets with diagnostic/therapeutic potential and sug-
gest a myogenic progenitor as the origin of disease. Our
ongoing efforts towards classification of ASPS in the con-
text of other soft-tissue sarcomas and the development of
an ASPS cell line will further address the issue of cellular
origin. An equally important question concerns the exact
role of the ASPL-TFE3 fusion protein in tumorigenesis.
The ability of fusion proteins containing TFE3 to transac-
tivate e-box containing genes such as c-MET suggests that
certain facets of the transcriptome are related to ASPL-
TFE3 activity [17]. It is hoped that by making this array
data publically available we will promote additional
investigations centered on this unique malignancy and
provide a useful reference dataset for the wider classifica-
tion of soft-tissue sarcomas.
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